نبذة مختصرة : Background How coffee consumption relates to mortality in diverse European populations, with variable coffee preparation methods and customs, is unclear. Objectives To examine whether coffee consumption is associated with all-cause and cause-specific mortality. Design Prospective cohort study. Setting Ten European countries. Participants A total of 521,330 individuals enrolled in the European Prospective Investigation into Cancer and Nutrition (EPIC). Main outcome measures Hazard ratios (HRs) and 95% confidence intervals(CIs) estimated using multivariable Cox proportional hazards models. The association of coffee with serum biomarkers of liver function, inflammation, and metabolic health was evaluated in the EPIC Biomarkers sub-cohort (n=14,800). Results During a mean follow-up of 16.4 years, 41,693 deaths occurred. Compared with non-consumers, participants in the highest quartile of coffee consumption experienced statistically significant lower all-cause mortality (Men: HR=0.88, 95%CI: 0.82-0.95; P-trend<0.001; Women: HR=0.93, 95%CI: 0.87-0.98; P-trend=0.009). Inverse associations were also observed for digestive disease mortality for men (HR=0.41, 95%CI: 0.32-0.54; P-trend<0.0001) and women (HR=0.60, 95%CI: 0.46-0.78; P-trend<0.0001). Among women only, there was a statistically significant inverse association between coffee and circulatory disease mortality, (HR=0.78, 95%CI: 0.68-0.90; P-trend<0.001), cerebrovascular disease mortality (HR=0.70, 95%CI: 0.55-0.90; P-trend=0.002), and a positive association between coffee and ovarian cancer mortality (HR 1.31, 95% CI: 1.07-1.61; P-trend 0.02). In the EPIC-biomarkers sub-cohort, higher coffee consumption was associated with lower serum alkaline phosphatase, alanine transaminase, aspartate transaminase, and C-reactive protein. Limitation Reverse causality may have led to spurious findings; however, results did not differ following exclusion of participants who died within 8-years of baseline. The study is also limited by a single assessment of coffee ...
No Comments.